21:51 , Mar 7, 2019 |  BC Extra  |  Financial News

Follow-on roundup: Horizon, Apellis, Epizyme

Horizon, Apellis and Epizyme each priced follow-ons raising a total of $552 million. Horizon Pharma plc (NASDAQ:HZNP) raised $300 million late Wednesday through the sale of 12 million shares at $24.50. The price is a...
16:15 , Feb 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Scleroderma Patient sample and mouse studies suggest inhibiting EZH2 could help treat scleroderma. In fibroblasts from patients with diffuse cutaneous scleroderma, levels of EZH2 mRNA were higher than in fibroblasts from healthy volunteers. In...
20:33 , Dec 6, 2018 |  BC Innovations  |  Translation in Brief

Opening chromatin: long-term detriment?

An Institute for Research in Biomedicine team has shown increasing chromatin accessibility in cancer could promote tumor aggressiveness, not reduce tumor mutation burden (TMB) as previously thought. The findings, reported last month in Nature Cell...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
19:35 , Oct 5, 2018 |  BC Week In Review  |  Financial News

Epizyme raises $75M follow-on

Epizyme Inc. (NASDAQ:EPZM) raised $75 million on Oct. 2 through the sale of 8.3 million shares at $9 in a follow-on underwritten by Jefferies. The price is a 7% discount to Epizyme’s close of $9.71...
19:09 , Oct 3, 2018 |  BC Extra  |  Financial News

GW, Epizyme, Kala price follow-ons

GW Pharmaceuticals plc (NASDAQ:GWPH), Epizyme Inc. (NASDAQ:EPZM) and Kala Pharmaceuticals Inc. (NASDAQ:KALA) each priced follow-ons late Tuesday, raising a total of $437 million. GW raised $300 million through the sale of 1.9 million ADSs at...
17:27 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

FDA lifts holds on Epizyme, Sarepta programs

FDA lifted separate clinical holds on tazemetostat from Epizyme Inc. (NASDAQ:EPZM) and a gene therapy program targeting micro-dystrophin from Sarepta Therapeutics Inc. (NASDAQ:SRPT), the companies said Sept. 24. Epizyme is reopening enrollment in all of...
22:32 , Sep 24, 2018 |  BC Extra  |  Clinical News

FDA lifts holds on Epizyme, Sarepta programs

FDA lifted separate clinical holds on tazemetostat from Epizyme Inc. (NASDAQ:EPZM) and a gene therapy program targeting micro-dystrophin from Sarepta Therapeutics Inc. (NASDAQ:SRPT), the companies said Monday. Epizyme is reopening enrollment in all of its...
01:46 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

Unsaturated remyelination

Enzymes downstream in cholesterol biosynthesis could provide new ways to stimulate remyelination that avoid the baggage of previously identified multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo...
17:41 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Epizyme falls on DLBCL discontinuations for tazemetostat

Epizyme Inc. (NASDAQ:EPZM) lost $3.10 (24%) to $9.90 on Aug. 2 after discontinuing development of tazemetostat both as monotherapy and in combination with prednisolone to treat diffuse large B cell lymphoma (DLBCL). The news comes...